"Buy Peptides from South Africa's Most Trusted Source - Free Delivery Over R 2500"

ARA 290


Anti-inflammation, stimulation of red blood cell production in bone marrow, diabetis and aids diebetic neuropathy, fast wound healing, reduces scarring.

SKU: d776cba86fce-2-1 Category: Tags: , ,

Scientific Name : ARA 290
Clinical Test Expectation:Anti-inflammation, stimulation of red blood cell production in bone marrow, diabetis and aids diebetic neuropathy, fast wound healing, reduces scarring.
MG Strength:  16mg per vial

Detailed Product Information

This peptide is a small peptide derived from the helix beta domain of erythropoietin (EPO). EPO has long been know to exhibit actions beyond the stimulation of red blood cell production in bone marrow. The glycoprotein, which is made in the kidney, has been found to stimulate blood vessel growth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabetic neuropathy. ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood ell production[1]. This peptide has completed phase II trials and is in preparation to enter phase III trials for a variety of applications in diabetes and the autoimmune sarcoidosis. Right now, the peptide is of active interest for its ability to control neuropathic pain, but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, as an immune modulatory drug, and as a potential treatment for systemic lupus erythematosus (lupus or SLE)

ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density

Small nerve fiber loss and damage (SNFLD) is a frequent complication of sarcoidosis that is associated with autonomic dysfunction and sensory abnormalities, including pain syndromes that severely degrade the quality of life. SNFLD is hypothesized to arise from the effects of immune dysregulation, an essential feature of sarcoidosis, on the peripheral and central nervous systems. Current therapy of sarcoidosis-associated SNFLD consists primarily of immune suppression and symptomatic treatment; however, this treatment is typically unsatisfactory. This peptide is a small peptide engineered to activate the innate repair receptor that antagonizes inflammatory processes and stimulates tissue repair. Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms. In addition to improved patient-reported symptom-based outcomes, ARA 290 administration was also associated with a significant increase in corneal small nerve fiber density, changes in cutaneous temperature sensitivity, and an increased exercise capacity as assessed by the 6-minute walk test. On the basis of these results and of prior studies, This peptide is a potential disease-modifying agent for treatment of sarcoidosis-associated SNFLD.

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. This peptide, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. This peptide (4 mg) or placebo were self-administered subcutaneously daily for 28 d and the subjects followed for an additional month without further treatment. No potential safety issues were identified. Subjects receiving ARA 290 exhibited an improvement in hemoglobin A(1c) (Hb A(1c)) and lipid profiles throughout the 56 d observation period. Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation.

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception

This peptide is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer. The analgesic effect of ARA 290 is mediated by its anti-inflammatory and immunomodulatory functions, or more specifically, by targeting the innate repair receptor (IRR) to down-regulate inflammation to alleviate neuropathic pain. However, whether other mechanisms or pathways are involved in ARA 290-mediated analgesic effect remains elusive. In this study, we are particularly interested in whether ARA 290 could directly target peripheral nociceptors by blocking or influencing receptors in pain sensation. Using calcium imaging, cell culture and behavioral tests, we demonstrated that ARA 290 was able to specifically inhibit TRPV1 channel activity, and relieve the mechanical hypersensitivity induced by capsaicin. Our study suggested that ARA 290 could potentially function as a novel antagonist for TRPV1 channel. This finding would not only contribute to the development of new pain treatment using ARA 290, but also help to improve our understanding of the integration between the immune system and the peripheral nervous system.

Additional information : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883966/

Mixing and our recommended dosage

You inject 2ml water into the vial of ARA 290 from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 0.3 on the syringe each night before bed and inject it into the tummy under the skin into the fatty skin layer. A vial should last 7 days.

Read more about our products here : FAQ’s

View more products here : More Products

Affiliate Partner : Visit Now